SynthesisObesity surgery2026
Evaluating the Role of Ketamine in Multimodal Analgesia for Postoperative Pain Management in Bariatric Surgery: A Meta-Analysis of Randomized Controlled Trials.
Synthesis in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Explainable artificial intelligence for postoperative analgesia risk stratification and clinical decision support in abdominal surgery.Frontiers in digital health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ketamine, an NMDA receptor antagonist, is increasingly investigated for its analgesic and opioid-sparing effects in multimodal pain management. Bariatric surgery poses unique challenges due to obesity-related risks and opioid sensitivity. This meta-analysis evaluates ketamine's efficacy and safety in reducing postoperative pain and opioid consumption in this high-risk patient population. We searched PubMed, Scopus, the Web of Science, and the Cochrane library for randomized controlled trials using tailored search strategies up to 2025. Eligibility was based on the PICO framework, focusing on bariatric surgery patients receiving ketamine versus placebo, with primary outcomes of opioid consumption and VAS pain scores. The study included 12 randomized controlled trials with 1,019 patients. Ketamine significantly reduced total opioid consumption within 24 hours (MD -5.87; 95% CI [-10.37, -1.38], p = 0.01) and VAS pain scores at 4 hours (MD -0.81; 95% CI [-1.52, -0.10], p = 0.03). Postoperative adverse events were significantly lower (OR 0.42; 95% CI [0.29, 0.62], p < 0.01), while no significant differences were observed for the duration of anesthesia, length of stay, estuation time, postoperative nausea and vomiting, or hemodynamic parameters. Sensitivity analyses confirmed result consistency. In summary, ketamine shows potential as an adjunct to multimodal analgesia in bariatric surgery, with reductions in opioid use and early postoperative pain observed across included studies. Although the limited number of trials and heterogeneity in study designs, these findings should be considered hypothesis-generating, and Low-dose ketamine should be considered as an adjunct for bariatric analgesia, particularly within ERAS protocols, but caution is necessary in patients prone to psychomimetic side effects.
Indexed as
Identifiers
41840313What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.